Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.
about
Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience.Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma.The direction of travel to better outcomes for patients with oesophago-gastric cancer.Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions.What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives
P2860
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Genomic Heterogeneity as a Bar ...... stroesophageal Adenocarcinoma.
@en
Genomic Heterogeneity as a Bar ...... stroesophageal Adenocarcinoma.
@nl
type
label
Genomic Heterogeneity as a Bar ...... stroesophageal Adenocarcinoma.
@en
Genomic Heterogeneity as a Bar ...... stroesophageal Adenocarcinoma.
@nl
prefLabel
Genomic Heterogeneity as a Bar ...... stroesophageal Adenocarcinoma.
@en
Genomic Heterogeneity as a Bar ...... stroesophageal Adenocarcinoma.
@nl
P2093
P2860
P50
P1433
P1476
Genomic Heterogeneity as a Bar ...... astroesophageal Adenocarcinoma
@en
P2093
Aaron R Thorner
Adam J Bass
Agoston T Agoston
Andres Gelrud
Andrew Dunford
Blase Polite
Bruce M Wollison
Byung-Hoon Min
Carrie Fitzpatrick
Christopher Weber
P2860
P356
10.1158/2159-8290.CD-17-0395
P577
2017-10-04T00:00:00Z